BackSinovac Biotech, Overview

Sinovac Biotech, Net Tangible Assets

Latest net tangible assets for SVA: $6.4B.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$6.40B

Peer trimmed avg / median

Loading

Sinovac Biotech, Net Tangible Assets History

Loading

Sinovac Biotech, vs. peers: Net Tangible Assets Comparison

Loading

Sinovac Biotech, Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sinovac Biotech, (SVA) FAQ

As of the most recent data (December 2025), SVA shows a net tangible assets of $6.4B. Scroll down for historical charts and peer comparison views.

Tracking SVA's net tangible assets over time shows whether Sinovac Biotech, is scaling, shrinking, or reshaping that part of the business. The current reading is $6.4B Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Sinovac Biotech,'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $6.4B) with ownership activity and broader fundamentals.

Sinovac Biotech,'s net tangible assets is $6.4B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.